Jag Capital Management, LLC Vertex Pharmaceuticals Inc Transaction History

Jag Capital Management, LLC

$725 Million
Q2 2024

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	SELL	$407.69 - $446.08 $5.6 Million - $6.13 Million	-13,736 Reduced 46.71%	15,674 $6.55 Million
Q4 2023 Feb 08, 2024	SELL	$343.0 - $410.68 $4.38 Million - $5.25 Million	-12,776 Reduced 30.28%	29,410 $12 Million
Q3 2023 Nov 15, 2023	SELL	$338.18 - $362.46 $195,806 - $209,864	-579 Reduced 1.35%	42,186 $14.7 Million
Q2 2023 Sep 07, 2023	SELL	$314.42 - $351.91 $219,465 - $245,633	-698 Reduced 1.61%	42,765 $15 Million
Q2 2023 Aug 11, 2023	SELL	$314.42 - $351.91 $713,418 - $798,483	-2,269 Reduced 5.03%	42,825 $15.1 Million
Q1 2023 Sep 07, 2023	SELL	$283.23 - $323.1 $166,539 - $189,982	-588 Reduced 1.33%	43,463 $13.7 Million
Q1 2023 Sep 01, 2023	SELL	$283.23 - $323.1 $166,256 - $189,659	-587 Reduced 1.33%	43,523 $13.7 Million
Q1 2023 May 10, 2023	SELL	$283.23 - $323.1 $435,890 - $497,250	-1,539 Reduced 3.3%	45,094 $14.2 Million
Q4 2022 Sep 07, 2023	BUY	$285.76 - $321.48 $350,341 - $394,134	1,226 Added 2.86%	44,051 $12.7 Million
Q4 2022 Sep 01, 2023	BUY	$285.76 - $321.48 $367,201 - $413,101	1,285 Added 3.0%	44,110 $12.7 Million
Q4 2022 Feb 08, 2023	BUY	$285.76 - $321.48 $155,739 - $175,206	545 Added 1.18%	46,633 $13.5 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $1.69 Million - $1.88 Million	6,159 Added 15.42%	46,088 $13.3 Million
Q2 2022 Aug 01, 2022	BUY	$234.96 - $292.55 $8.51 Million - $10.6 Million	36,199 Added 970.48%	39,929 $11.3 Million
Q1 2022 May 11, 2022	BUY	$221.42 - $260.97 $825,896 - $973,418	3,730 New	3,730 $802,000
Q3 2021 Oct 21, 2021	SELL	$181.39 - $202.99 $676,584 - $757,152	-3,730 Closed	0 $0
Q1 2021 Apr 23, 2021	SELL	$207.02 - $241.31 $872,589 - $1.02 Million	-4,215 Reduced 53.05%	3,730 $802,000
Q4 2020 Feb 01, 2021	SELL	$207.01 - $276.09 $12.1 Million - $16.1 Million	-58,263 Reduced 88.0%	7,945 $1.88 Million
Q3 2020 Oct 21, 2020	SELL	$255.65 - $303.1 $159,781 - $189,437	-625 Reduced 0.94%	66,208 $18 Million
Q2 2020 Jul 23, 2020	BUY	$225.48 - $295.8 $542,279 - $711,399	2,405 Added 3.73%	66,833 $19.4 Million
Q1 2020 Apr 16, 2020	BUY	$199.77 - $247.81 $7.92 Million - $9.83 Million	39,654 Added 160.06%	64,428 $15.3 Million
Q4 2019 Jan 27, 2020	BUY	$166.71 - $223.91 $4.13 Million - $5.55 Million	24,774 New	24,774 $5.42 Million
Q2 2019 Jul 22, 2019	SELL	$164.61 - $190.37 $8.72 Million - $10.1 Million	-53,003 Closed	0 $0
Q1 2019 Apr 15, 2019	BUY	$163.73 - $194.7 $719,920 - $856,095	4,397 Added 9.05%	53,003 $9.75 Million
Q4 2018 Jan 16, 2019	BUY	$151.91 - $192.21 $7.38 Million - $9.34 Million	48,606 New	48,606 $8.05 Million
Q3 2018 Oct 23, 2018	SELL	$167.73 - $192.74 $2.97 Million - $3.41 Million	-17,695 Closed	0 $0
Q2 2018 Jul 20, 2018	SELL	$145.72 - $169.96 $6.35 Million - $7.4 Million	-43,560 Reduced 71.11%	17,695 $3.01 Million
Q1 2018 Apr 23, 2018	BUY	$151.6 - $177.13 $9.29 Million - $10.9 Million	61,255 New	61,255 $9.98 Million
Q4 2017 Jan 23, 2018	SELL	$137.28 - $155.55 $4.61 Million - $5.22 Million	-33,583 Closed	0 $0
Q3 2017 Oct 16, 2017	BUY	$148.13 - $162.24 $4.97 Million - $5.45 Million	33,583	33,583 $5.11 Million

Others Institutions Holding VRTX

# of Institutions

1,707

Shares Held

226M

Call Options Held

1.2M

Put Options Held

1.59M

Capital World Investors Los Angeles, CA

26.7M
Shares

$12.7 Billion
2.1% of portfolio
Vanguard Group Inc Valley Forge, PA

23M
Shares

$10.9 Billion
0.21% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$10.1 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.7M
Shares

$5.56 Billion
0.24% of portfolio
Capital Research Global Investors Los Angeles, CA

8.54M
Shares

$4.05 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $122B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jag Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jag Capital Management, LLC with notifications on news.

Account